Plain-English translation of NCT04875611 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called Nivolumab to see if it can help people with nasopharyngeal cancer (cancer of the upper throat behind the nose) whose cancer has grown or come back after chemotherapy. Nivolumab is an immunotherapy — a type of drug that helps your immune system recognize and fight cancer cells. The study will involve about 32 patients and will measure how well this medication works in this specific situation.
When nasopharyngeal cancer comes back or progresses after standard chemotherapy, treatment options become very limited. This trial exists to see whether this medication — which works by boosting the body's own immune system — might offer hope for patients in this difficult situation.
You likely qualify if…
You likely don't qualify if…
You would receive infusions of the medication on a regular schedule at the study clinic. The trial involves visits to monitor how your body is responding to treatment, including blood tests, imaging scans, and check-ups with the research team. The study will track your health and your cancer's response over time to see whether this medication is helping you.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Poland